{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance
Rhythm Pharmaceuticals, Inc. has recently revised its evaluation amid changing market dynamics. The stock is currently priced at $111.55, reflecting a strong annual return of 124.40%. Technical indicators present a mixed outlook, with bullish signals in some areas and bearish tendencies in others, highlighting ongoing volatility.
Is Rhythm Pharmaceuticals, Inc. technically bullish or bearish?
As of October 24, 2025, Rhythm Pharmaceuticals, Inc. is in a bullish trend with strong momentum indicators, despite some bearish signals in RSI and KST, and has significantly outperformed the S&P 500 with a year-to-date return of 97.34%.
Is Rhythm Pharmaceuticals, Inc. technically bullish or bearish?
As of October 24, 2025, Rhythm Pharmaceuticals, Inc. has a bullish trend with strong moving averages and MACD indicators, despite some bearish signals from RSI and KST, and has significantly outperformed the S&P 500 with a year-to-date return of 97.34%.
Is Rhythm Pharmaceuticals, Inc. technically bullish or bearish?
As of October 24, 2025, Rhythm Pharmaceuticals, Inc. shows a bullish trend supported by positive MACD signals and strong performance, despite some bearish RSI readings, outperforming the S&P 500 with a year-to-date return of 97.34%.
Rhythm Pharmaceuticals Hits New 52-Week High of $109.68
Rhythm Pharmaceuticals, Inc. achieved a new 52-week high of USD 109.68 on October 15, 2025, reflecting a significant one-year performance increase. The company, with a market capitalization of USD 6,627 million, has notable financial metrics but remains loss-making, navigating challenges in the biotechnology sector.
Rhythm Pharmaceuticals Hits New 52-Week High of $106.84
Rhythm Pharmaceuticals, Inc. achieved a new 52-week high of USD 106.84 on October 14, 2025, reflecting strong performance in the pharmaceuticals sector. The company has seen a 156.52% increase in stock price over the past year, significantly outperforming the S&P 500, with an impressive return on equity of 1,528.51%.
Is Rhythm Pharmaceuticals, Inc. technically bullish or bearish?
As of August 27, 2025, Rhythm Pharmaceuticals shows a bullish trend overall, despite mixed signals from technical indicators, and has significantly outperformed the S&P 500 with a year-to-date return of 76.03% compared to 12.22%.
Is Rhythm Pharmaceuticals, Inc. overvalued or undervalued?
As of November 2, 2021, Rhythm Pharmaceuticals, Inc. is considered risky and overvalued due to significant negative financial metrics, including a Price to Book Value of 228.70 and a P/E ratio of -36.41, despite a strong year-to-date return of 76.03%.
Is Rhythm Pharmaceuticals, Inc. technically bullish or bearish?
As of June 27, 2025, the market trend is bullish with strong indicators like MACD and Bollinger Bands supporting this view, despite mixed signals from KST and OBV, while Dow Theory shows a mildly bearish stance weekly but bullish monthly.
Is Rhythm Pharmaceuticals, Inc. overvalued or undervalued?
As of November 2, 2021, Rhythm Pharmaceuticals, Inc. is considered overvalued with a risky valuation grade, highlighted by a Price to Book Value of 228.70 and an ROE of -926.82%, despite a 48.39% stock return over the past year, which outperformed the S&P 500's 10.26%.
Is Rhythm Pharmaceuticals, Inc. technically bullish or bearish?
As of May 2, 2025, the technical trend is bullish, supported by strong MACD and Bollinger Bands indicators, with the stock outperforming the S&P 500 over the past 1 and 3 years.
Who are in the management team of Rhythm Pharmaceuticals, Inc.?
As of March 2022, Rhythm Pharmaceuticals' management team is led by Dr. David Meeker as Chairman, President, and CEO, alongside a diverse Board of Directors that includes Dr. Camille Bedrosian, Mrs. Lynn Tetrault, Mr. Stuart Arbuckle, Mr. Todd Foley, and Ms. Jennifer Good.
What does Rhythm Pharmaceuticals, Inc. do?
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company that develops peptide therapeutics for rare genetic metabolic disorders. As of March 2025, it reported net sales of $33 million and a net loss of $49 million, with a market cap of approximately $3.94 billion.
How big is Rhythm Pharmaceuticals, Inc.?
As of Jun 18, Rhythm Pharmaceuticals, Inc. has a market capitalization of $3.94 billion, with net sales of $136.86 million and a net profit of -$168.69 million over the last four quarters. Shareholder's funds are $21.73 million, and total assets amount to $393.47 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
